Variable cMyBP-C expression from cell to cell in a MYBPC3c.927–2 A>G hiPSC-CM model recapitulates HCM patient phenotype

Abstract Background Hypertrophic cardiomyopathy (HCM) is frequently associated with mutations in cardiac myosin binding protein C (cMyBP-C; MYBPC3 ) and cMyBP-C haploinsufficiency. Previously we discovered burst-like transcription of MYBPC3 and unequal amounts of wild type cMyBP-C from cardiomyocyte to cardiomyocyte in HCM-patient’s myocardium. The present study introduces human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) carrying the patient-specific heterozygous MYBPC3 c.927–2 A > G mutation and the respective isogenic control to examine in long-term culture whether comparable pathophysiological features exist in vitro. Methods We generated a human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) model harboring the patient-specific MYBPC3 c.927–2 A > G splice-site mutation. An isogenic control line was used for direct comparison. We assessed cMyBP-C protein expression, transcriptional dynamics, contractile function, and calcium handling, and compared the cellular phenotype to heart tissue from the HCM patient with the same mutation. Results cMyBP-C haploinsufficiency in MYBPC3 c.927–2 A> G - hiPSC-CMs was confirmed by Western blot. Immunostaining showed myofibrillar disarray and an increasing proportion of cMyBP-C-negative CMs over time for mutant hiPSC-CMs, closely mirrored the variable cMyBP-C protein expression observed in HCM-patient’s myocardium. RNA-FISH revealed variable MYBPC3 transcription from cell to cell, likely contributing to cMyBP-C expression heterogeneity. Twitch shortening velocity slowed over time while Ca²⁺ transient kinetics accelerated in mutant hiPSC-CMs. Transcriptomic analysis revealed dysregulation of pathways associated with contraction, calcium handling, and HCM. Conclusions This study presents a validated hiPSC-based model of MYBPC3 -associated HCM that captures the variability in protein expression and functional phenotype observed in patient heart tissue. Our findings support the relevance of single-cell transcriptional variability in HCM pathogenesis and highlight the utility of this model for future studies.

Authors

Institutions

Publication Details

Journal
Stem Cell Research & Therapy
Published
2026-05-19
DOI
https://doi.org/10.1186/s13287-026-05063-9
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Variable cMyBP-C expression from cell to cell in a MYBPC3c.927–2 A>G hiPSC-CM model recapitulates HCM patient phenotype

Birgit Piep, Sarah A. Konze, Judith Montag, Kathrin Kowalski et al.
Stem Cell Research & Therapy
Cardiomyopathy and Myosin Studies
article

Variable cMyBP-C expression from cell to cell in a MYBPC3c.927–2 A>G hiPSC-CM model recapitulates HCM patient phenotype

Birgit Piep, Sarah A. Konze, Judith Montag, Kathrin Kowalski, Theresia Kraft, Jana Teske, Ante Radocaj, Maike Kosanke, Joachim D. MEISSNER, Karina Ivaskevica, Robert Zweigerdt
article en

Abstract

Abstract Background Hypertrophic cardiomyopathy (HCM) is frequently associated with mutations in cardiac myosin binding protein C (cMyBP-C; MYBPC3 ) and cMyBP-C haploinsufficiency. Previously we discovered burst-like transcription of MYBPC3 and unequal amounts of wild type cMyBP-C from cardiomyocyte to cardiomyocyte in HCM-patient’s myocardium. The present study introduces human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) carrying the patient-specific heterozygous MYBPC3 c.927–2 A > G mutation and the respective isogenic control to examine in long-term culture whether comparable pathophysiological features exist in vitro. Methods We generated a human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) model harboring the patient-specific MYBPC3 c.927–2 A > G splice-site mutation. An isogenic control line was used for direct comparison. We assessed cMyBP-C protein expression, transcriptional dynamics, contractile function, and calcium handling, and compared the cellular phenotype to heart tissue from the HCM patient with the same mutation. Results cMyBP-C haploinsufficiency in MYBPC3 c.927–2 A> G - hiPSC-CMs was confirmed by Western blot. Immunostaining showed myofibrillar disarray and an increasing proportion of cMyBP-C-negative CMs over time for mutant hiPSC-CMs, closely mirrored the variable cMyBP-C protein expression observed in HCM-patient’s myocardium. RNA-FISH revealed variable MYBPC3 transcription from cell to cell, likely contributing to cMyBP-C expression heterogeneity. Twitch shortening velocity slowed over time while Ca²⁺ transient kinetics accelerated in mutant hiPSC-CMs. Transcriptomic analysis revealed dysregulation of pathways associated with contraction, calcium handling, and HCM. Conclusions This study presents a validated hiPSC-based model of MYBPC3 -associated HCM that captures the variability in protein expression and functional phenotype observed in patient heart tissue. Our findings support the relevance of single-cell transcriptional variability in HCM pathogenesis and highlight the utility of this model for future studies.

Stem Cell Research & Therapy
Leibniz University Hannover (DE), Medizinische Hochschule Hannover (DE), MSB Medical School Berlin (DE)
Openalex Percentile: Top 6%
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.